{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:28:46Z","timestamp":1768789726818,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,8,2]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              The contribution of apolipoprotein A\u2010I (apoA\u2010I) to coronary heart disease (\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              ) risk stratification over and above high\u2010density lipoprotein cholesterol (\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C) is unclear. We studied the associations between plasma levels of\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoA\u2010I, either alone or combined, with risk of\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              events and cardiovascular risk factors among apparently healthy men and women.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoA\u2010I levels were measured among 17\u00a0661 participants of the\n              <jats:styled-content style=\"fixed-case\">EPIC<\/jats:styled-content>\n              (European Prospective Investigation into Cancer)\u2010Norfolk prospective population study. Hazard ratios for\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              events and distributions of risk factors were calculated by quartiles of\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoA\u2010I. Results were validated using data from the\n              <jats:styled-content style=\"fixed-case\">ARIC<\/jats:styled-content>\n              (Atherosclerosis Risk in Communities) and\n              <jats:styled-content style=\"fixed-case\">WHS<\/jats:styled-content>\n              (Women's Health Study) cohorts, comprising 15\u00a0494 and 27\u00a0552 individuals, respectively. In\n              <jats:styled-content style=\"fixed-case\">EPIC<\/jats:styled-content>\n              \u2010Norfolk, both\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoA\u2010I quartiles were strongly and inversely associated with\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              risk. Within\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C quartiles, higher apoA\u2010I levels were not associated with lower\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              risk; in fact,\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              risk was higher within some\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C quartiles. ApoA\u2010I levels were associated with higher levels of\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              risk factors: higher body mass index, HbA1c, non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C, triglycerides, apolipoprotein B, systolic blood pressure, and C\u2010reactive protein, within fixed\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C quartiles. In contrast,\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C levels were consistently inversely associated with overall\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              risk and\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              risk factors within apoA\u2010I quartiles (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.001). These findings were validated in the\n              <jats:styled-content style=\"fixed-case\">ARIC<\/jats:styled-content>\n              and\n              <jats:styled-content style=\"fixed-case\">WHS<\/jats:styled-content>\n              cohorts.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Our findings demonstrate that apoA\u2010I levels do not offer predictive information over and above\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C. In fact, within some\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C quartiles, higher apoA\u2010I levels were associated with higher risk of\n              <jats:styled-content style=\"fixed-case\">CHD<\/jats:styled-content>\n              events, possibly because of the unexpected higher prevalence of cardiovascular risk factors in association with higher apoA\u2010I levels.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Clinical Trial Registration<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">URL<\/jats:styled-content>\n              :\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier:\n              <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n              00000479.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.117.006636","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:10:09Z","timestamp":1501805409000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Association of High\u2010Density Lipoprotein\u2010Cholesterol Versus Apolipoprotein A\u2010I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer\u2010Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study"],"prefix":"10.1161","volume":"6","author":[{"given":"Julian C.","family":"van Capelleveen","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea E.","family":"Bochem","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands"},{"name":"Department of Medicine, Columbia University, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Matthijs","family":"Boekholdt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Mora","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron C.","family":"Hoogeveen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wensheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, University of New South Wales, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Tall","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aeilko H.","family":"Zwinderman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick J.","family":"Wareham","sequence":"additional","affiliation":[{"name":"Medical Research Council Epidemiology Unit, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay\u2010Tee","family":"Khaw","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, University of Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60312-2"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206797"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609581"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1619"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01647.x"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.258673"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79048"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.12.067"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu171"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0146-z"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250601"},{"key":"e_1_3_5_14_2","first-page":"2499","article-title":"Lipid\u2010related markers and cardiovascular disease prediction","volume":"307","author":"Emerging Risk Factors Collaboration","year":"2012","unstructured":"Emerging Risk Factors Collaboration , Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstr\u00f6m J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RPF, Assmann G, D'Agostino RB, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, G\u00f3mez\u2010de\u2010la\u2010C\u00e1mara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FGR, Casiglia E, Hofman A, Salomaa V, Barrett\u2010Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw K\u2010T, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid\u2010related markers and cardiovascular disease prediction. JAMA. 2012;307:2499\u20132506.","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_5_15_2","first-page":"95","article-title":"EPIC\u2010Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer","volume":"80","author":"Day N","year":"1999","unstructured":"Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC\u2010Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80(suppl 1):95\u2013103.","journal-title":"Br J Cancer"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.04.010"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/38.5.658"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115184"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00041-0"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.14.7.1098"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050613"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-11-201112060-00006"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000133317.49796.0e"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61076-4"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.060"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/07435809609043765"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(94)90162-7"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.18.6.0318"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.9.1481"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.155333"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.117.006636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:54:16Z","timestamp":1715597656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.117.006636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8,2]]}},"alternative-id":["10.1161\/JAHA.117.006636"],"URL":"https:\/\/doi.org\/10.1161\/jaha.117.006636","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]},"assertion":[{"value":"2017-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e006636"}}